The cost savings for health plans would increase if the therapy were used after the first recurrence of Clostridioides difficile infection (CDI). A fecal microbiota–based therapy for recurrent ...

FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) -The U.S. health regulator on Wednesday approved Switzerland-based Ferring Pharmaceuticals' fecal ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

The FDA approved the first fecal transplant therapy, Rebyota, for people with ongoing Clostridioides difficile, ABC News reported Nov. 30. Rebyota is a therapy manufactured by stool donations that are ...

Please provide your email address to receive an email when new articles are posted on . High-dose VE303 prevented more cases of recurrent C. difficile infection compared with a lower dose medication ...

Adding fecal microbiota therapy to standard care for steroid-ineligible severe alcoholic-associated hepatitis appeared safe and effective in a small randomized trial from India. Survival at 90 days ...

A therapy using fecal matter to combat a bad bug in the gut will now be regulated by the federal government, to the consternation of some physicians. The bug is Clostridium difficile, or C. diff, and ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Direct fecal transplants (or fecal bacteriotherapy), where there is a transfer gut microbiota from healthy donors, have shown great promise in treating a range of diseases. An alternative name for the ...

Swiss pharma giant Roche on Monday said it would buy Telavant, an immunology company developing a promising treatment for inflammatory bowel disease, in a deal worth more than $7 billion, as the ...

Nov 30 (Reuters) - The U.S. health regulator on Wednesday approved Switzerland-based Ferring Pharmaceuticals' fecal transplant-based therapy to reduce the recurrence of a bacterial infection, making ...